Description
Diagnostic Markets for Women’s Health (Pregnancy and Ovulation, Bone Density, Prenatal Screening, Ultrasound, Mammography, Pap Smear, Colposcopy, HPV, UTI, and Other Testing)
Kalorama Information’s report on Women’s Health Diagnostic Markets takes a solid look at the current and developing world markets for key diagnostic tests aimed at the health of women. The report presents market developments in women’s health diagnostics, including in-depth analysis of the following testing fields:
- Ovarian Cancer Testing
- Urinary Tract Infections
- Neonatal Jaundice
- Autoimmune Disease
- Cystic Fibrosis
- Pregnancy and Ovulation Testing
- Bone Density Testing
- Prenatal Screening
- Ultrasound
- Mammography
- Pap Smears
- Colposcopy
- HPV Testing
This particular study projects market growth for these tests to 2018. Market segments covered include European, US, Brazilian, Chinese and Japanese markets among others,
Globally women live longer than men. Thus healthcare systems need to change the understanding of the differences, in terms of health, between the women and men and to turn that knowledge into improved medical practice. Diagnostics are an important part of this change.
Women’s Health Diagnostic Markets also reviews the nature and direction of research and trends, and gives insight into some issues facing the industry. The report profiles several key companies, including large companies that have made names for themselves in the field, as well as smaller firms with market niches. These companies are involved in developing and marketing over the counter (OTC), point of care (POC) in vitro diagnostic (IVD) tests and screening systems. Some of the companies profiled include:
- Nova Biomedical
- Philips Healthcare
- Siemens Healthcare
- Somagen Diagnostics
- GE Healthcare
- GenMark Diagnostics
- Hologic
- Immco Diagnostics
- Luminex
Sales projections are modeled on an investigation of today’s market conditions and on investigations into the development of new products by top tier competitors. The information offered in this study is the result of data gathered from company product literature and other corporate brochures and documents, as well as information found in the scientific and trade press. In addition, interviews were conducted with company executives and researchers.
Kalorama Information’s report on Women’s Health Diagnostic Markets takes a solid look at the current and developing world markets for key diagnostic tests aimed at the health of women. The report presents market developments in women’s health diagnostics, including in-depth analysis of the following testing fields:
- Ovarian Cancer Testing
- Urinary Tract Infections
- Neonatal Jaundice
- Autoimmune Disease
- Cystic Fibrosis
- Pregnancy and Ovulation Testing
- Bone Density Testing
- Prenatal Screening
- Ultrasound
- Mammography
- Pap Smears
- Colposcopy
- HPV Testing
This particular study projects market growth for these tests to 2018. Market segments covered include European, US, Brazilian, Chinese and Japanese markets among others,
Globally women live longer than men. Thus healthcare systems need to change the understanding of the differences, in terms of health, between the women and men and to turn that knowledge into improved medical practice. Diagnostics are an important part of this change.
Women’s Health Diagnostic Markets also reviews the nature and direction of research and trends, and gives insight into some issues facing the industry. The report profiles several key companies, including large companies that have made names for themselves in the field, as well as smaller firms with market niches. These companies are involved in developing and marketing over the counter (OTC), point of care (POC) in vitro diagnostic (IVD) tests and screening systems. Some of the companies profiled include:
- Nova Biomedical
- Philips Healthcare
- Siemens Healthcare
- Somagen Diagnostics
- GE Healthcare
- GenMark Diagnostics
- Hologic
- Immco Diagnostics
- Luminex
Sales projections are modeled on an investigation of today’s market conditions and on investigations into the development of new products by top tier competitors. The information offered in this study is the result of data gathered from company product literature and other corporate brochures and documents, as well as information found in the scientific and trade press. In addition, interviews were conducted with company executives and researchers.
Table of Contents
1.0 Executive Summary
1.1 Methodology
2.0 Introduction
2.1 Female Health: Room for Improvement
2.2 Perspective on Women’s Health
2.3 The Way Women and Men Develop Disease Is Different
2.3.1 Pain
2.3.2 The Heart
2.3.3 The Brain
2.3.4 Emotions
2.3.5 Bone Structure
2.3.6 Alcohol
2.3.7 Drug Side Effects
2.3.8 Smoking
2.3.9 Fertility
2.3.10 STIs/HIV
2.3.11 Autoimmune Disease
2.3.12 Cancer
2.3.13 Musculoskeletal Health
2.3.14 Birth Defects
2.3.15 Urinary Tract Infections
2.4 Key Leading Causes of Death in Females
2.5 Demographics
2.6 What Claims Women’s Lives
2.7 Key Trends and Issues in Women’s Diagnostics
2.7.1 OVA1
2.7.2 CA-125
2.7.3 HER2
2.8 Understanding the Molecular Basis of Disease
2.8.1 Managing Cancer Disease and Costs through Reimbursement
2.8.2 Ultrasound and Mammography Use Grows
3.0 Market Developments in Women’s Health Diagnostics
3.1 Quest and Hologic Team Up
3.2 Quest Genetic Testing for Breast Cancer Risk
3.3 Sequenom, Quest Collaborate on Noninvasive Prenatal Testing
3.4 Partnering to Make Personalized Infertility Treatment Possible
3.5 Co-Marketing of Full-Length HLA Gene Sequencing Products
3.6 Acquisition Strengthens Theranostics Development
3.7 Trinity Biotech Acquisition
3.8 Noninvasive Prenatal Test Significantly Reduces False Positive Rate
3.9 Proteome Sciences, Fisher Scientific Sign Agreement on Cancer Tests
3.10 Agreement on Fetal and Maternal Monitoring Software
3.11 Distribution Agreement for OTC Women’s Health Diagnostics
3.12 Women’s Health Cancer Diagnostics Company Raises $11.3 Million
3.13 Crowd Funding for At-Home Breast Exam Device
3.14 $13M Series A Round for Ultrasound Fibroid Device
3.15 FDA Clears Femur Fracture Test
3.16 FDA 510(k) Clearance for Female Incontinence Device
3.17 GE PMA for extended labeling for Senographe Mammography
3.18 FDA Clears MicroDose Mammography
3.19 FDA ABUS Approval
3.20 FDA Approval for Imaging Software System for Ultrasound
3.21 EU Nod for Breast Tissue Screening System
3.22 Cervical Cancer Screening Test Concerns
3.23 New Smartphone App Detects Newborn Jaundice in Minutes
4.0 Pregnancy and Ovulation
Key Trend
4.1 Perspective on Testing
4.1.1 Digital Testing
4.1.2 Testing for Placental Growth Factor and Pre-eclampsia
4.1.3 Lab Developed Tests
4.2 OTC Pregnancy Self-Test Market
4.3 Lab-Based Fertility Testing Market
4.4 Lab-Based Torch Testing Market
4.5 Abbott Diagnostics
4.6 Alere Inc.
4.7 biomerieux SA
4.8 Church & Dwight Co. Inc
4.9 Dialab GMBH
4.10 Prestige Diagnostics
4.11 Roche Diagnostics
4.12 Siemens Healthcare Diagnostics
5.0 Bone Density Testing
Key Trend
5.1 Alarming Rise of Osteoporosis
5.2 Propelling the Need for Detection
5.3 DEXA and Competing Technologies
5.4 Bone Densitometer Market
5.5 GE Healthcare
5.6 Hologic
5.7 Osteometer MediTech
6.0 Prenatal Screening
Key Trend
6.1 Invasive Testing
6.2 Noninvasive Testing
6.3 The Impact of Prenatal Genetic Testing
6.4 DNA Assay Market
6.5 Prenatal Carrier and Fetus Screening Market
6.6 PerkinElmer
6.7 Quest Diagnostics
6.8 ScreenCell
6.9 Sequenom
6.10 Laboratory Corporation of America
7.0 Ultrasound
Key Trend
7.1 History and Perspective
7.2 Nuchal Translucency
7.3 Speckle Reduction
7.4 Volumetric Imaging
7.5 Follicular Tracking
7.6 Obstetrics and Gynecology
7.7 Breast Imaging
7.8 Ob/Gyn Market
7.9 Breast Imaging Market
7.10 Analogic
7.11 Philips Healthcare
7.12 Siemens Healthcare
7.13 GE Healthcare
7.14 Hitachi Aloka Medical Ltd.
7.15 Supersonic Imagine
8.0 Mammography
Key Trend
8.1 Perspective
8.1.1 Economics of Routine Screening
8.2 Transitioning to Digital
8.3 Computer-Aided Detection
8.3.1 A Second Opinion
8.3.2 Analyzing Tumor Characteristics
8.4 Mammography Systems Market
8.5 CAD Market
8.6 Carestream Health
8.7 FujiFilm Medical Systems USA
8.8 GE Healthcare
8.9 Hologic
8.10 iCAD Inc
8.11 Parascript LLC
8.12 R2 Technology
9.0 Pap Smears
Key Trend
9.1 Testing for Cervical Cancer
9.1.1 Types of Screening
9.2 Cervical Cancer Vaccines
9.3 A Market Need
9.4 IVD Market
9.5 BD
9.6 BioReference Laboratories
9.7 BioSciCon
9.8 Hologic
9.9 Innogenetics NV
10.0 Colposcopy
Key Trend
10.1 Colposcopy Biopsy
10.2 Abnormal Pap Smear Results
10.3 Routine Use But Mature Market
10.3.1 Primary and Secondary Screening
10.4 Colposcopy Systems Market
10.5 CooperSurgical
10.6 DySIS Medical
10.7 Guided Therapeutics
10.8 Leisegang
10.9 NeoDiagnostix
11.0 HPV Testing
Key Trend
11.1 HPV Infection
11.1.1 Infection in Females
11.1.2 High Risk Types
11.1.3 HPV Major Cause of Cervical Cancer
11.2 HPV Test
11.3 Vaccine Issues
11.4 Strong Market Expected
11.4.1 IVD Market
11.5 Abbott Molecular
11.6 Hologic
11.7 Qiagen Benelux BV
11.8 Roche Diagnostics
12.0 Ovarian Cancer
Key Trend
12.1 Types of Ovarian Cancer
12.2 Pelvic Examinations
12.3 Tumor Markers, AFP, HE4
12.4 CA-125 Antigen
12.5 CA-125 Market
12.6 Avant Diagnostics Inc.
12.7 Biosystems International
12.8 Fujirebio Diagnostics
12.9 Myriad Genetics Inc.
13.0 Urinary Tract Infections
Key Trend
13.1 Leading Cause of Morbidity and Death
13.1.1 Impact
13.1.2 Impact on Women
13.1.3 E. coli the Key Culprit
13.2 UTI Molecular Testing Market
13.3 i-Health Inc.
13.4 Liofilchem
13.5 Rheonix
13.6 Somagen Diagnostics
14.0 Neonatal Jaundice
Key Trend
14.1 Issues Involving Bilirubin
14.2 Two Factors in Neonates
14.3 Risk Factors
14.4 Smart Phone App
14.5 Bilirubin Testing Market
14.6 Instrumentation Laboratory
14.7 Nova Biomedical
14.8 Siemens Healthcare Diagnostics
14.9 Wako Diagnostics
14.10 Roche Diagnostics
15.0 Autoimmune Disease
Key Trend
15.1 Types of Autoimmune Disease
15.2 Genetic Factors
15.3 Impact on Females
15.4 Female Lab-Based Immunoassay Autoimmune Testing Market
15.5 Aesku.Diagnostics
15.6 AXA Diagnostics SRL
15.7 Bio-Rad Laboratories
15.8 Euroimmun AG
15.9 Immco Diagnostics
15.10 Kronus
15.11 Phadia
15.12 XDx
16.0 Cystic Fibrosis
Key Trend
16.1 Affecting the Entire Body
16.2 Reduced Life Expectancy
16.3 Genetics
16.4 Chronic Infections
16.5 Females Worse Than Males
16.6 Genetic Testing Market
16.7 AutoGenomics
16.8 GenMark Diagnostics
16.9 Illumina
16.10 Luminex
16.11 ScheBo – Biotech AG
16.12 Sequenom
